MX2018011536A - Composiciones y métodos para el uso de eflornitina, y derivados y análogos de la misma para tratar cánceres, incluyendo gliomas. - Google Patents

Composiciones y métodos para el uso de eflornitina, y derivados y análogos de la misma para tratar cánceres, incluyendo gliomas.

Info

Publication number
MX2018011536A
MX2018011536A MX2018011536A MX2018011536A MX2018011536A MX 2018011536 A MX2018011536 A MX 2018011536A MX 2018011536 A MX2018011536 A MX 2018011536A MX 2018011536 A MX2018011536 A MX 2018011536A MX 2018011536 A MX2018011536 A MX 2018011536A
Authority
MX
Mexico
Prior art keywords
eflornithine
glioma
compositions
methods
analogs
Prior art date
Application number
MX2018011536A
Other languages
English (en)
Inventor
A Levin Victor
Original Assignee
Orbus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbus Therapeutics Inc filed Critical Orbus Therapeutics Inc
Publication of MX2018011536A publication Critical patent/MX2018011536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La eflornitina es un agente que puede usarse para tratar el glioma, especialmente el glioma de grado II o grado III de la OMS, tal como el glioma anaplasico; la eflornitina puede suprimir o prevenir las mutaciones en el glioma que pueden hacer que el glioma progrese a un mayor grado; las composiciones y metodos pueden incluir eflornitina o un derivado o analogo de eflornitina, junto con otros agentes tales como agentes anti-neoplasicos convencionales para el tratamiento del glioma, inhibidores del transporte de poliamina, analogos de poliamina o inhibidores de la S-adenosilmetionina descarboxilasa.
MX2018011536A 2016-03-24 2017-03-16 Composiciones y métodos para el uso de eflornitina, y derivados y análogos de la misma para tratar cánceres, incluyendo gliomas. MX2018011536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662312623P 2016-03-24 2016-03-24
PCT/US2017/022718 WO2017165187A1 (en) 2016-03-24 2017-03-16 Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas

Publications (1)

Publication Number Publication Date
MX2018011536A true MX2018011536A (es) 2019-07-04

Family

ID=59896896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011536A MX2018011536A (es) 2016-03-24 2017-03-16 Composiciones y métodos para el uso de eflornitina, y derivados y análogos de la misma para tratar cánceres, incluyendo gliomas.

Country Status (13)

Country Link
US (2) US20170273926A1 (es)
EP (1) EP3432872B1 (es)
JP (2) JP2019509349A (es)
KR (2) KR20220140027A (es)
CN (1) CN109152758A (es)
AU (2) AU2017236646A1 (es)
CA (1) CA3018821C (es)
DK (1) DK3432872T3 (es)
ES (1) ES2896735T3 (es)
IL (1) IL261920A (es)
MX (1) MX2018011536A (es)
PL (1) PL3432872T3 (es)
WO (1) WO2017165187A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN117530943A (zh) 2016-10-06 2024-02-09 奥巴斯治疗股份有限公司 用于施用依氟鸟氨酸的制剂
KR20200055722A (ko) 2017-09-20 2020-05-21 오클라호마 메디컬 리써치 화운데이션 약물 내성 신경아교종의 치료
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
US20230404642A1 (en) * 2022-06-01 2023-12-21 Syncromune, Inc. Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2083030B (en) * 1980-08-23 1984-03-07 Merrell Toraude & Co Fluorinated pentene diamine derivatives
WO1997045817A1 (en) 1996-05-24 1997-12-04 Eduard Karel De Jong System with and method of cryptographically protecting communications
EP0886519A1 (en) 1996-11-01 1998-12-30 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6646149B1 (en) * 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
US6949679B1 (en) * 1998-04-21 2005-09-27 Universite Laval Polyamine transport inhibitors
US20030203956A1 (en) 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US6630511B2 (en) 2000-08-01 2003-10-07 Rolland F. Hebert Water-soluble salts of 2-difluoromethyl-2,5-diaminopentanoic acid (DFMO)
WO2003015763A1 (en) * 2001-08-13 2003-02-27 Board Of Regents, The University Of Texas System Adjuvant chemotherapy for anaplastic gliomas
SE0401871D0 (sv) 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
US7655678B2 (en) 2004-11-30 2010-02-02 Council of Scientfic & Industrial Research Pharmaceutical composition for the management of tumors
US9072778B2 (en) 2005-12-20 2015-07-07 University Of Hawaii Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
US8497398B1 (en) 2007-05-02 2013-07-30 University Of Central Florida Research Foundation, Inc. Polyamine transporter selective compounds as anti-cancer agents
WO2009065090A2 (en) 2007-11-14 2009-05-22 University Of Hawaii Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition
WO2010028099A1 (en) * 2008-09-03 2010-03-11 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
SG10201500048SA (en) * 2010-01-05 2015-03-30 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
US20130197088A1 (en) 2010-03-12 2013-08-01 Robert A. Casero, JR. Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO)
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
US9901563B2 (en) * 2013-03-11 2018-02-27 Delmar Pharmaceuticals, Inc. Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
US9346741B2 (en) 2012-03-28 2016-05-24 University Of Central Florida Research Foundation, Inc. Polyamine transport selective therapeutic agents with enhanced stability
WO2014085579A1 (en) * 2012-11-30 2014-06-05 Northeastern University Copolymers for the delivery of drugs into cells

Also Published As

Publication number Publication date
CA3018821A1 (en) 2017-09-28
AU2023200537A1 (en) 2023-03-02
ES2896735T3 (es) 2022-02-25
EP3432872A4 (en) 2019-11-13
EP3432872B1 (en) 2021-08-25
JP2022095882A (ja) 2022-06-28
KR20180124976A (ko) 2018-11-21
DK3432872T3 (da) 2021-10-11
AU2017236646A1 (en) 2018-11-15
US20170273926A1 (en) 2017-09-28
CN109152758A (zh) 2019-01-04
CA3018821C (en) 2023-03-14
US20190091187A1 (en) 2019-03-28
PL3432872T3 (pl) 2022-01-03
WO2017165187A1 (en) 2017-09-28
KR20220140027A (ko) 2022-10-17
JP2019509349A (ja) 2019-04-04
IL261920A (en) 2018-10-31
EP3432872A1 (en) 2019-01-30
KR102452370B1 (ko) 2022-10-07

Similar Documents

Publication Publication Date Title
MX2018011536A (es) Composiciones y métodos para el uso de eflornitina, y derivados y análogos de la misma para tratar cánceres, incluyendo gliomas.
MY185614A (en) Use of myostatin inhibitors and combination therapies
ZA202007007B (en) Mcl-1 inhibitors
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
PH12020550936A1 (en) Combination drug including tlr7 agonist
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
MX2020009256A (es) Compuestos para el tratamiento de cancer.
MX2016012779A (es) Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
NZ792518A (en) Formulations for administration of eflornithine
AR103110A1 (es) Métodos de combinación para el tratamiento de cánceres
MX2018004664A (es) Antagonistas de ep4.
PH12018501443A1 (en) Methods of administering hepcidin
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
ZA201901367B (en) Inhibition of olig2 activity
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
MX2017015532A (es) Terapia de combinacion pac-1.
MX2017014084A (es) Formulaciones de deposito inyectables.
NZ733451A (en) Combination therapy for pulmonary hypertension